Mushrooms Archives - Green Market Report

Debra BorchardtApril 29, 2020
shutterstock_1517440529-scaled.jpg?fit=960%2C640&ssl=1

7min20850

Specialty life science company Revive Therapeutics Ltd. (CSE: RVV) has said that it will investigate novel oral dosage forms of psilocybin, such as oral dissolvable thin films or tablets, based on its wholly-owned patent-pending psilocybin formulations and its exclusive licensed drug delivery technology from the Wisconsin Alumni Research Foundation.

“We are expanding our psilocybin-based pharmaceutical portfolio with unique oral dosage and drug delivery forms that will target and have the potential to treat diseases and disorders currently not investigated with psychedelic compounds,” said Michael Frank, Revive’s, Chief Executive Officer. “We are combining our robust intellectual property portfolio in both psychedelic formulations and our drug delivery technology which is unique within the industry, and leveraging our research partnership with the University of Wisconsin-Madison to establish a specialty portfolio of psilocybin-based pharmaceuticals that we can advance to clinical trials and partnerships with other life sciences companies.”

The company said in a statement that through initial evaluations with its research team, it has found there are several unique parallels between the company’s intellectual property portfolio of psilocybin-based formulations and delivery mechanism and the drug delivery technology, which is comprised of tannin-chitosan composites that have been studied with cannabidiol in the past.  Revive said it intends to research both delivery mechanisms in parallel as each provides its own unique qualities such as the potential of rapid onset of action and time-release compositions.

New Interest in Psilocybin

Psilocybin is being viewed as a treatment for several conditions including drug-resistant depression. Studies have been performed to illustrate the efficacy of psilocybin for this specific purpose. One completed study found that psilocybin produced substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. The study was published in 2016, and wrote that “At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. Participants attributed improvements in attitudes about life/self, mood, relationships, and spirituality to the high-dose experience, with >80% endorsing moderately or greater increased well-being/life satisfaction.”

According to the World Health Organization, almost 350 million people worldwide were affected by depression in 2016. Common antidepressant drugs help maintain the balance of various hormones and chemicals in the brain, which assists in the treatment of depression.

The Center for Disease Control and Prevention (CDC), reported that the percentage of people above the age of 12 years using antidepressants in the U.S. rose to 12.7% in 2011-2014. According to MedGadget, the antidepressant drug market was valued at $13.69 billion in 2018 and is expected to reach $15.88 billion by 2025. The CDC said that in the U.S., antidepressants were the most commonly prescribed drugs in 2013 and from over 16 million long term users, around 70% are female.

Psilocin Acquisition

In March, Revive completed its acquisition of Psilocin Pharma Corp., a specialty psychedelic sciences company focused on the development of Psilocybin-based therapeutics for significant unmet medical needs including rare and orphan indications. Psilocin developed patent-pending formulation and production solutions for the active compound Psilocybin.  The process encompassed with its intellectual property cover methods of production of Psilocybin-based formulations.

In a statement, the company noted that Psilocin has also developed formulations to date which include the Hydroxy Line.  The line will include PSY-0.1 -Capsules- PSY-0.2 -Sublingual Spray- PSY-0.3 -Gel Cap- PSY-0.4/0.5 -Effervescent Tablets-and PSY-0.6 -Breath Strips.  The precisely dosed formulations will work with both natural and synthetically derived Psilocybin which will be targeted for clinical research and subject to U.S. Food and Drug Administration (“FDA”) approval in the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and a number of other diseases.  Psilocin’s range of products have been engineered to work synergistically with the body’s own natural pathways of absorption while offering a contemporary approach to consumption

Best Delivery Method

Revive believes that the most optimal delivery method to deliver psilocybin will be in the form of both an oral dissolvable tablet and an oral thin film strip, commonly recognized as a ‘Breath Strip’.  The company said that it is preparing its formulation development plans to pursue clinical studies for indications currently not being evaluated with psilocybin.

The company reported that it has key provisional patent applications with the U.S. Patent and Trademark Office that cover methods of production of psilocybin-based formulations, including sublingual sprays, effervescent tablets, hard-shell capsules, sublingual and transmucosal delivery systems (i.e. gum drops, oral strips, dosing pens). In addition to those patent applications, Revive has a patent-pending portfolio that includes Psilocybin extraction and crystallization methodologies.

The delivery technology is a natural, non-toxic, biodegradable, and biocompatible composite that combines a tannin material, which is derived from a plant group having antibacterial, antifungal, antioxidant and wound healing properties, and a chitosan material, which is derived from the crustacean group having blood-clotting and antimicrobial properties. The delivery technology has a rapid onset of action and controlled or sustained release potential capabilities and may allow combining multiple extracts from mushrooms in one formulation.

Revive is also exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza strains including COVID-19.


StaffApril 22, 2020
mushroom.jpg?fit=960%2C640&ssl=1

5min17000

The Campaign to Decriminalize Nature DC (DNDC) released the results of a new poll on April 21 that showed support for mushroom decriminalization in Washington DC. The “Initiative 81, the “Entheogenic Plant and Fungus Policy Act of 2020,” has enough support to pass in the District of Columbia according to a survey completed by Fairbank, Maslin, Maullin, Metz & Associates (FM3).

The poll sponsored by the New Approach PAC demonstrated that a majority of DC voters support Initiative 81, a measure that would make enforcement of existing restrictions on plant medicines or entheogens among the Metropolitan Police Department’s lowest law enforcement priorities. Of those polled, 51% support the initiative based on the text of the measure alone. When presented with a plain-language explanation, that support grows to 60% and continues to increase and solidify as voters learn more.

Here’s the initial language that didn’t have as positive of a response:

ENTHEOGENIC PLANT AND FUNGUS POLICY ACT OF 2020. If enacted, this Initiative would: Make the investigation and arrest of adults for non-commercial planting, cultivating, purchasing, transporting, distributing, possessing, and/or engaging in practices with entheogenic plants and fungi among the Metropolitan Police Department’s lowest law enforcement priorities; and codify that the people of the District of Columbia call upon the Attorney General for the District of Columbia and the United States Attorney for the District of Columbia to cease prosecution of residents of the District of Columbia for these activities

Here’s the easier to understand language:

It would change current law having to do with plant medicines known as entheogens, which include substances
like psilocybin, the active ingredient in “magic mushrooms”; cacti which contain mescaline, iboga, which contains
ibogaine and ayahuasca, which contains DMT. The measure would make investigation and arrest of adults for
non-commercial growing, gathering, and gifting of these plant medicines among the lowest law enforcement
priorities for the District of Columbia. The measure instructs the DC Attorney General to not prosecute people
arrested for entheogens. The measure does not legalize these substances, allow their retail sales, or permit
marketing of any products containing these substances

One issue that was identified was the lack of knowledge about the products. The survey determined that fewer than one-quarter have a close tie to someone who has used psilocybin; very few have personally used ayahuasca, mescaline or iboga, or know someone who has. Having said that, many DC voters have a connection to
someone who has experienced the type of mental health issues the substances can treat.

Among the more than 800 likely DC voters reached by phone as part of this poll, prioritizing law enforcement’s role in reducing violent crime and protecting personal freedom were consistently cited as top reasons for supporting Initiative 81.

These results come as the DNDC faces unprecedented challenges due to the COVID-19 coronavirus pandemic. Necessary social-distancing measures, including DC Mayor Murial Bowser’s stay-at-home order, have made traditional in-person petitioning and signature collection impossible. To preserve ballot access during this public health emergency, DNDC has requested that the DC Board of Elections and DC Council find alternatives to the in-person petition process. Time is running out for DNDC to qualify for the November ballot with 30,000 signatures needed by Monday, July 6th.

“This poll demonstrates the broad support for Initiative 81 in the District of Columbia and reaffirms the importance of putting the “Entheogenic Plant and Fungus Policy Act of 2020,” on the November ballot,” said Melissa Lavasani, the proposer of Initiative 81. “Despite the current public health crisis, DC voters have made clear that they are ready to change how DC approaches entheogens. Now our campaign must make sure that voters have the opportunity to do so.”


Debra BorchardtApril 7, 2020
mushroom.jpg?fit=960%2C640&ssl=1

4min25260

NewLeaf Brands Inc. (CSE: NLB) (OTC: NLBIF) has signed a letter of intent to purchase Colorado-based  Mydecine Group in an all-stock deal valued at $850,000.  Mydecine is a vertically integrated company engaged to utilize the vast medicinal, health and wellness capabilities of the many compounds found in various strains of mushroom and fungi as a whole.

“We’ve been watching and closely monitoring the progress of the mycology space for some time now. Given that we are located in the home state to first decriminalize psilocybin in the U.S., the Company has had a unique opportunity to get a jump on the potential industry as a whole,” said Joshua Bartch CEO of NewLeaf Brands in a statement. “So far, Denver and Oakland have decriminalized psilocybin, while Oregon has a measure to legalize the substance as soon as this year! We share a common vision of Mydecine in the sense of seeing the vast potential of mycology as a whole, not just the compound psilocybin. Numerous other compounds found in fully legal fungi are very exciting and hold the potential to make truly revolutionary discoveries, IP and products.  We see this as an incredibly early opportunity with enormous potential upside.”

Mydecine has three wholly-owned divisions, “Mydecine Farms”, “Mydecine Wellness”, and “Psydecine Labs.” The company aims to be an industry pioneer in the cultivation, processing, product development, and research and development of the many beneficial and exciting compounds that are found in various strains of mushroom and fungi from all around the world.

The company noted in a statement that numerous compounds found in various strains of mushroom and fungi are already being used to develop treatments for health conditions such as depression, PTSD and opiate addiction. Meanwhile, in 2019, the National Alliance on Mental Illness had stated that 1 in 6 youths aged 6-17 in the U.S. experience a mental health disorder each year and 1 in 25 U.S. adults experience a serious mental illness each year.

NewLeaf Brands is a CBD lifestyle Company. It owns the subsidiaries We are Kured, LLC, Drink Fresh Water, LLC, ReLyfe Brand, LLC and TeaLief Brand, LLC. The company’s main business activities encompass the development, marketing, and distribution of CBD products (including vaporizer pens/cartridges, hot/cold tea, softgel capsules and beverages) throughout North AmericaSouth America, and Europe. In addition, NewLeaf Brands, Inc. has extensive retail and cultivation land investments in Oregon, USA.

The NewLeaf stock trades at seven cents per share and the company has a market cap of roughly $2 million.

 

 


Noemi GonzalesApril 3, 2020
792399-v0_5-GMR-BC-FB.png?fit=960%2C469&ssl=1

6min19151

“Magic Mushrooms and Marijuana: a Great Trip to Know, Understand the Risks, Cultivate and use Cannabis and Psychedelic Mushrooms even for Medical Use. A High Trip to the Knowledge You Will Not Forget!” by Tommy Smith – Review

 Now here’s a dynamic duo of topics to discuss: cannabis and mushrooms.

Author Tommy Smith has put together a very solid compilation of data focused on helping the reader better understand the risks, how to cultivate, various uses, and other useful information when it comes to both cannabis and magic mushrooms. There is still much inaccurate information prevalent on these topics so the more genuine content we see circulating then all the better.

This book will teach you how to create an ideal environment to grow mushrooms in your home, decide whether or not to grow indoors or out, how to begin growing marijuana, how to identify various types of mushrooms and so much more.

Did you know that around 5,000 BC that the Chinese were among the first cultures to regularly cultivate and consume cannabis?

See? You’re learning already!

-Topic Focus-

So much good content packed into this book about both cannabis and mushrooms. Where to begin?

You will find this book useful if you:

  • Want to learn how to begin growing cannabis
  • Want to learn how to begin growing mushrooms
  • Want to learn about the medicinal benefits of both cannabis and mushrooms
  • Are interested in the history surrounding cannabis and mushrooms

About the Author

“Magic Mushrooms and Marijuana: a Great Trip to Know, Understand the Risks, cultivate and use cannabis and Psychedelic Mushrooms even for medical use. A high trip to the knowledge you will not forget!” author Tommy Smith quickly displays both expertise on these topics and a passion for them as you read this book.

You can tell that Tommy truly cares about sharing this information in the way that the book is written as well as the fact that so much useful content is shared for such a low price. Very generous.

-Reading Experience-

This book gets right to work with no fluff or hyperbole and dives right into the history and starts from the ground up with an introduction to what cannabis is, what THC is, and a brief history of it’s legalization status over the years. It felt like author Tommy Smith just couldn’t wait to start sharing his expertise with the reader.

There are many of us who struggle to learn tasks such as cultivation so having a guide that is simple to follow is an incredibly useful tool. The information presented is done so in a way that is easy to interpret and take action from.

Not only are the medicinal benefits of cannabis and mushroom use discussed here, but so are the potential risks that accompany such use. Many people involved in these industries tend to display consumption in a positive light without discussing potential risks so being willing to address the potential negatives of such consumption lends the writer a degree of credibility.

-Summary-

“Magic Mushrooms and Marijuana: a Great Trip to Know, Understand the Risks, cultivate and use cannabis and Psychedelic Mushrooms even for medical use. A high trip to the knowledge you will not forget!” by Tommy Smith is over 300 pages that get right to work teaching you useful content and is only $6.90 (at the time of writing) so you can’t really go wrong grabbing your copy.

The content is clearly written in a way that communicates how familiar the author is with these topics while also making cultivation feel all the more accessible. If you are not already an expert on cannabis then there is definitely much here for you to dive into. Even the more veteran among us can learn a thing or three from this useful book.

If you are ready to begin your own educational journey regarding cannabis and mushrooms then get your copy here: https://www.amazon.com/Magic-Mushrooms-Marijuana-Understand-Psychedelic

 


StaffJanuary 21, 2020
shutterstock_1526869721-scaled.jpg?fit=720%2C960&ssl=1

3min34410

Just as the psilocybin mushroom market begins to heat up, one enterprising entrepreneur has quickly snapped up the trademark for the word “Psilocybin.” Marijuana Moment picked up on the founder’s notice on LinkedIn that the word had been trademarked. That post has since disappeared and while there is no mention of the trademark happening on the company’s website, the tiny TM does appear after each mention of the word Psilocybin on the company’s website.

The company sells chocolate bars, that don’t seem to contain any mushroom ingredients. In fact, there is little in the way of a description as to how the chocolate is made or sourced. It says the bars “have been created as a gateway to educate you on what is next for medicinal mushroom health and healing.” It does say that all the products are sold out.

Scarlet Ravin describes her company Psilocybin™️ as “a community-based support system holding a sacred knowing for others to come back to their knowing of their God-self.” She describes herself as being “known for her visionary Branding and Marketing which has led her companies to the front of the market allowing multiple press mentions and forward-thinking concepts that grab the attention of the mass market.”

Ravin told Marijuana Moment that she “plans to contribute 10 percent of profits to the Multidisciplinary Association for Psychedelic Studies (MAPS), which is involved in researching the therapeutic benefits of psychedelic substances.”

Marijuana Trademarks Not Allowed

Psilocybin mushrooms are also a schedule 1 substance under the Controlled Substance Act like marijuana. The U.S. Patent Trade Office stated that marijuana is still prohibited from U.S. trademark registration. “The CSA prohibits, among other things, manufacturing, distributing, dispensing, or possessing certain controlled substances, including marijuana. 21 U.S.C. §§812, 841(a)(1), 844(a). Therefore, the USPTO refuses registration when an application identifies goods encompassing CBD or other extracts of marijuana because such goods are unlawful under federal law and do not support valid use of the applied-for mark in commerce.”

Marijuana Moment noted that this trademark is “Specifically for educational materials and it’s listed on the supplemental register, rather than the principal register, which means it would be incumbent upon the brand to prove that it has earned distinctiveness of the mark if the issue went to court.”

 

 

 


Noemi GonzalesJanuary 17, 2020
shutterstock_266222585-scaled.jpg?fit=960%2C815&ssl=1

5min26691

Your Psilocybin Mushroom Companion: An Informative, Easy-to-Use Guide to Understanding Magic Mushrooms―From Tips and Trips to Microdosing and Psychedelic Therapy

Your Psilocybin Mushroom Companion” by Michelle Janikian is a useful book when it comes to shedding light on the benefits and misconceptions of mushroom/Psilocybin use. The level of information available is quite surprising and it does a great job of diffusing lingering myths on the subject of Psilocybin.

Not sure if you want the book just yet?

No worries, we reviewed it for you!

-Topic Focus-

The author, Michelle Janikian, focuses on the implementation side of mushroom use. Here you will find information about the best ways to guide others during their psychedelic trips, microdosing, how to maximize mental health benefits, and more.

There is much misinformation on this subject so seeing some focus allotted toward the dispelling of such myths in “Your Psilocybin Mushroom Companion” is refreshing.

Reading about the notion that mushrooms can improve your life in a variety of ways is certainly interesting. The discussion on the benefits gained from microdosing is impressive and learning how to guide others seems to be a useful skill.

Reading about how microdosing can increase physical stamina, boost your mood, and elevate your clarity of thought is very fascinating and worth further exploration.

About the Author

Michelle Janikian is a journalist/author who has experience writing for publications such as Rolling Stone, High Times, Teen Vogue, and currently writes for Playboy.

Michelle studied writing and psychology at Sarah Lawrence College and the majority of her writing content focuses on drug policy, education, and the growing legal cannabis industry. Her passion for these subjects becomes clear as you read her content.

She also displays expertise in investigating the potential medicinal benefits of plants/substances that currently possess a degree of social stigma.

Michelle was raised in New Jersey but she was born in New York.

You can learn more about the author at michellejanikian.com

-Reading Experience-

The writing level is very appropriate and welcoming for beginners to begin to understand microdosing, mushroom use, and more.

You do not need to be up to speed on deep scientific terminology to keep up with and utilize this book. Again, this is a great book for the beginner to learn about the introductory topics to Psilocybin use and to dispel potential misconceptions on the topic.

There is minimal fluff so the book gets right to the point and flows well. It should not take more than a few days to get through and makes for a great reference guide to look back to when needed.

It is kind of exciting to consider the potential implications in the future that Psilocybin could have on the medical industry after reading this book.

-Summary-

“Your Psilocybin Mushroom Companion” is an ideal tool for a beginner to understand the basics of microdosing, dispelling myths, and learning about the potential benefits that come with microdosing Psilocybin mushrooms.

The book is to the point, accessible, and is a quick read. No advanced scientific degrees required to keep up with this one.

The author does a great job of demonstrating her expertise on the topic as she guides us through some useful information on Psilocybin mushrooms and their implementation.

You can see for yourself how Psilocybin can benefit your life by checking out Michelle’s book here:

https://www.amazon.com/Your-Psilocybin-Mushroom-Companion-Easy/dp/1612439470


Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Friday afternoon.

We respect your privacy. See our privacy policy.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 3 days

We will be live blogging from all week. Head to the website – link in bio – if you didn’t m…

@GreenMarketRpt – 3 days

⁦@PelorusEquityGr⁩ Upsizes Offering To $1 Billion

Back to Top

Don't Miss This Week's Groundbreaking News

Join the thousands of subscribers who stay informed with GMR's exclusive news briefs delivered directly to your inbox every Friday afternoon.

We respect your privacy. See our privacy policy.